down arrow

AbbVie, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00287Y1091
USD
228.71
-1.53 (-0.66%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

227.59230.94

52 Week

164.39244.81
Valuation
Technical
Day's Volume

CASH

3.73 M

Shareholding (Mar 2025)

FII

15.65%

Held by 646 FIIs

DII

54.54%

Held by 164 DIIs

Promoter

0.03%

How big is AbbVie, Inc.?

22-Jun-2025

As of Jun 18, AbbVie, Inc. has a market capitalization of approximately $333.93 billion, with net sales of $57.37 billion and a net profit of $4.16 billion over the last four quarters.

As of Jun 18, AbbVie, Inc. has a market capitalization of 333,933.93 million, classifying it as a Large Cap company.<BR><BR>As of the latest four quarters, AbbVie reported net sales of 57,367.00 million and a net profit of 4,163.00 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 3,325.00 million and total assets amounting to 135,161.00 million.

Read More

What does AbbVie, Inc. do?

22-Jun-2025

AbbVie, Inc. is a large-cap biopharmaceutical company focused on the discovery, development, and sale of pharmaceutical products, with recent net sales of $13.34 billion and a market cap of approximately $333.93 billion. Key financial metrics include a P/E ratio of 23.00 and a dividend yield of 251.41%.

Overview: <BR>AbbVie, Inc. is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and sale of pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13,343 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,279 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 333,933.93 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 23.00 <BR>Dividend Yield: 251.41% <BR>Debt Equity: 45.57 <BR>Return on Equity: 1,031.47% <BR>Price to Book: 235.16<BR><BR>Contact Details: <BR>Address: 1 N Waukegan Rd, NORTH CHICAGO IL: 60064-1802 <BR>Tel: 1 847 9327900 <BR>Website: https://www.abbvie.com/

Read More

Who are in the management team of AbbVie, Inc.?

22-Jun-2025

As of March 2022, AbbVie, Inc.'s management team includes Chairman and CEO Richard Gonzalez, Lead Independent Director Glenn Tilton, and independent directors Dr. Robert Alpern, Ms. Roxanne Austin, Mr. William Burnside, and Mr. Thomas Freyman.

As of March 2022, the management team of AbbVie, Inc. includes Mr. Richard Gonzalez, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Mr. Glenn Tilton is the Lead Independent Director. The board also comprises independent directors: Dr. Robert Alpern, Ms. Roxanne Austin, Mr. William Burnside, and Mr. Thomas Freyman.

Read More

Is AbbVie, Inc. overvalued or undervalued?

20-Sep-2025

As of July 31, 2025, AbbVie, Inc. is considered overvalued with a P/E ratio of 23 and an EV to EBITDA ratio of 15.67, despite a strong year-to-date return of 24.92%, as it has underperformed the S&P 500 over the past three years.

As of 31 July 2025, the valuation grade for AbbVie, Inc. has moved from very expensive to risky, indicating a shift in perception regarding its valuation. Based on the current metrics, AbbVie appears to be overvalued. The P/E ratio stands at 23, while its peers, such as Eli Lilly & Co. with a P/E of 40.89 and Johnson & Johnson at 26.18, suggest that AbbVie is trading at a lower multiple compared to some competitors, yet still reflects a high valuation in its own right. Additionally, the EV to EBITDA ratio is 15.67, which is higher than Merck & Co. at 12.15, further supporting the notion of overvaluation.<BR><BR>In terms of returns, AbbVie has outperformed the S&P 500 year-to-date with a return of 24.92% compared to the index's 12.22%. However, over the longer term, its 3-year return of 54.10% trails the S&P 500's 70.41%, indicating that while recent performance has been strong, it has not kept pace with broader market gains. Overall, AbbVie’s high valuation ratios and mixed performance relative to peers and the market suggest that it may be overvalued at its current price of 221.99.

Read More

Is AbbVie, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, AbbVie, Inc. has a mildly bullish technical trend, with mixed signals from indicators, underperforming the S&P 500 recently but outperforming it year-to-date.

As of 31 October 2025, the technical trend for AbbVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a mildly bullish stance on both weekly and monthly charts, and daily moving averages are also mildly bullish. However, the KST is bullish weekly but mildly bearish monthly, and Dow Theory reflects a mildly bearish weekly outlook against a bullish monthly view. <BR><BR>In terms of performance, AbbVie has underperformed the S&P 500 over the past week and month, with returns of -5.32% and -7.70% respectively, while it has outperformed the benchmark year-to-date with a return of 21.49% compared to 16.30%. Overall, the current technical stance is mildly bullish, but with some caution due to mixed signals from various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Debt company with Weak Long Term Fundamental Strength

  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Flat results in Jun 25

3

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 377,734 Million (Large Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

150.59%

stock-summary
Debt Equity

-349.80

stock-summary
Return on Equity

-8,165.01%

stock-summary
Price to Book

-2,064.12

Revenue and Profits:
Net Sales:
15,423 Million
(Quarterly Results - Jun 2025)
Net Profit:
931 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.38%
0%
7.38%
6 Months
22.08%
0%
22.08%
1 Year
29.61%
0%
29.61%
2 Years
58.66%
0%
58.66%
3 Years
39.75%
0%
39.75%
4 Years
92.44%
0%
92.44%
5 Years
113.19%
0%
113.19%

AbbVie, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is AbbVie, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for AbbVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a mildly bullish stance on both weekly and monthly charts, and daily moving averages are also mildly bullish. However, the KST is bullish weekly but mildly bearish monthly, and Dow Theory reflects a mildly bearish weekly outlook against a bullish monthly view. In terms of performance, AbbVie has underperformed the S&P 500 over the past week and month, with returns of -5.32% and -7.70% respectively, while it has outperformed the benchmark year-to-date with a return of 21.49% compared to 16.30%. Overall, the current technical stance is mildly bullish, but with some caution due to mixed signals from various indicators....

Read More

Is AbbVie, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for AbbVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals. The Bollinger Bands show a mildly bullish stance in both weekly and monthly time frames. Daily moving averages are mildly bullish, supporting a positive short-term outlook. However, the weekly KST is bullish, contrasting with the monthly KST being mildly bearish. Dow Theory reflects a mildly bearish weekly trend but a bullish monthly trend. In terms of performance, AbbVie has underperformed the S&P 500 over the past week and month, with returns of -7.05% and -9.38% compared to the S&P 500's 0.71% and 1.92%, respectively. However, it has outperformed the index year-to-date with a return of 19.28% versus 16.30%. Overall, the current technical stance is mildly bullish, but the mixed indicators suggest caution....

Read More

Is AbbVie, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for AbbVie, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. However, the KST is bullish weekly but mildly bearish monthly, and the Dow Theory indicates a mildly bearish weekly trend alongside a bullish monthly trend. The moving averages are mildly bullish on the daily chart. In terms of performance, AbbVie has underperformed the S&P 500 over the past week and month, with returns of -4.36% and -10.78% compared to the S&P 500's gains of 0.71% and 1.92%, respectively. However, it has outperformed the benchmark year-to-date with a return of 22.70% versus 16.30%. Overall, the current technical stance is mildly bullish, but the mixed signals suggest caution....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
9.99%
EBIT Growth (5y)
6.08%
EBIT to Interest (avg)
7.46
Debt to EBITDA (avg)
2.38
Net Debt to Equity (avg)
45.57
Sales to Capital Employed (avg)
0.76
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
263.15%
Pledged Shares
0
Institutional Holding
74.27%
ROCE (avg)
25.94%
ROE (avg)
300.50%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
240.68
EV to EBIT
23.05
EV to EBITDA
15.67
EV to Capital Employed
6.15
EV to Sales
7.09
PEG Ratio
1.44
Dividend Yield
245.64%
ROCE (Latest)
26.66%
ROE (Latest)
1031.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 265 Schemes (29.78%)

Foreign Institutions

Held by 646 Foreign Institutions (15.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 6.65% vs 4.31% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -31.69% vs -32.39% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15,423.00",
          "val2": "14,462.00",
          "chgp": "6.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,886.00",
          "val2": "7,078.00",
          "chgp": "11.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "782.00",
          "val2": "763.00",
          "chgp": "2.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3,766.00",
          "val2": "-2,428.00",
          "chgp": "-55.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "931.00",
          "val2": "1,363.00",
          "chgp": "-31.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "376.10%",
          "val2": "345.30%",
          "chgp": "3.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.71% vs -6.44% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -12.09% vs -59.04% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "56,334.00",
          "val2": "54,318.00",
          "chgp": "3.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25,011.00",
          "val2": "26,780.00",
          "chgp": "-6.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2,954.00",
          "val2": "2,360.00",
          "chgp": "25.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11,187.00",
          "val2": "-10,528.00",
          "chgp": "-6.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,246.00",
          "val2": "4,830.00",
          "chgp": "-12.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "295.10%",
          "val2": "332.90%",
          "chgp": "-3.78%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
15,423.00
14,462.00
6.65%
Operating Profit (PBDIT) excl Other Income
7,886.00
7,078.00
11.42%
Interest
782.00
763.00
2.49%
Exceptional Items
-3,766.00
-2,428.00
-55.11%
Consolidate Net Profit
931.00
1,363.00
-31.69%
Operating Profit Margin (Excl OI)
376.10%
345.30%
3.08%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 6.65% vs 4.31% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -31.69% vs -32.39% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
56,334.00
54,318.00
3.71%
Operating Profit (PBDIT) excl Other Income
25,011.00
26,780.00
-6.61%
Interest
2,954.00
2,360.00
25.17%
Exceptional Items
-11,187.00
-10,528.00
-6.26%
Consolidate Net Profit
4,246.00
4,830.00
-12.09%
Operating Profit Margin (Excl OI)
295.10%
332.90%
-3.78%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 3.71% vs -6.44% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -12.09% vs -59.04% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About AbbVie, Inc. stock-summary
stock-summary
AbbVie, Inc.
Pharmaceuticals & Biotechnology
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Company Coordinates stock-summary
Company Details
1 N Waukegan Rd , NORTH CHICAGO IL : 60064-1802
stock-summary
Tel: 1 847 9327900
stock-summary
https://www.abbvie.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."